MECHELEN, BELGIUM--(Marketwire - March 04, 2013) - Galapagos NV (Euronext: GLPG) announced
today
the appointment of Katrine Bosley to its Board of Directors as an
independent
Non-Executive Director.
Ms Bosley was appointed to fill the vacancy that has arisen on Galapagos'
Board
as a result of the recent resignation of Mr Ferdinand Verdonck, who has
been a
member of the Galapagos Board since the IPO of the Company in 2005.
"On behalf of the Board I sincerely thank Ferdinand for his exceptional
support
of the Company during the last eight years," Raj Parekh, Chairman of the
Board,
commented. "We all strongly appreciate Ferdinand's material role as a
Board
member in guiding Galapagos in its evolution and transformation from a
young
biotech company into a mature bio-pharmaceutical group, and we are very
grateful
for his constructive and stimulating contributions over such a long
period."
Katrine Bosley was until recently the CEO of Avila Therapeutics, a
targeted
covalent drug company. Avila established a number of strategic alliances
prior
to its acquisition by Celgene in 2012. Prior to Avila, Katrine was
Vice
President Business Development at Adnexus Therapeutics, a company
developing a
new class of protein therapeutics. Katrine joined Adnexus from Biogen Idec
where
she had roles in business development, commercial operations, and
portfolio
strategy in the U.S. and Europe. Earlier, she was part of the healthcare
team
at the venture firm Highland Capital Partners. Katrine graduated from
Cornell
University with a B.A. in biology and completed the Program for
Management
Development at Harvard Business School.
"We are very pleased that Katrine has agreed to become a member of the
Galapagos
Board of Directors. Her proven track record of scientific and
business
leadership, as well as her specific expertise in matters that are of
direct
importance for the Company's growth path, will make her an excellent
Board
member," commented Onno van de Stolpe, CEO of Galapagos.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline of four clinical, six
pre-clinical, and 30 discovery small-molecule and antibody programs
in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment
of rheumatoid arthritis and potentially other inflammatory diseases,
about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide
license
agreement whereby AbbVie will be responsible for further
development and
commercialization after Phase 2b. Galapagos has another selective
JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly
GLPG0778,
in-licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin
receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974
is the
first inhibitor of GPR43 to be evaluated clinically for the treatment of
IBD;
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus,
Argenta and
Fidelta, has over 800 employees and operates facilities in five countries,
with
global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
performance
or achievements of Galapagos, or industry results, to be materially
different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
on
such forward-looking statements. These forward-looking statements speak
only as
of the date of publication of this document. Galapagos expressly disclaims
any
obligation to update any such forward-looking statements in this document
to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
unless
required by law or regulation.
Katrine Bosley appointed to Galapagos' Board of Directors:
http://hugin.info/133350/R/1682611/550450.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1682611]
